Синдром Шегрена с дебютом в детском возрасте
Синдром Шегрена с дебютом в детском возрасте
Каледа М.И., Никишина И.П., Латыпова А.Н. Синдром Шегрена с дебютом в детском возрасте. Терапевтический архив. 2019; 91 (5): 54–60. DOI: 10.26442/00403660.2019.05.000189
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Цель исследования: провести анализ демографических данных, особенностей клинической картины и результатов лабораторно-инструментального обследования у пациентов детского возраста с первичным и вторичным синдромом Шегрена (СШ).
Материалы и методы. В исследование включены пациенты, последовательно госпитализированные в детское отделение НИИР им. В.А. Насоновой в период с января 2013 по декабрь 2018 г., которым по итогам обследования верифицирован диагноз СШ.
Результаты. Диагноз СШ установлен у 30 пациентов, среди которых было только 5 (16,7%) мальчиков, соотношение мальчиков и девочек 1:5. По итогам обследования верифицированы следующие диагнозы: у 4 – первичный СШ, у 9 – системная красная волчанка (СКВ) с СШ, у 10 – ювенильный ревматический артрит с СШ, у 3 – смешанное заболевание соединительной ткани, у 3 – перекрестный синдром, у 1 – системная склеродермия. Медиана возраста дебюта ревматического заболевания (РЗ) составила 10,4 (7,0; 13,75) года. Медиана длительности болезни на момент верификации СШ – 3,0 (0,85; 4,4) года. Рецидивирующие паротиты наблюдались у 8 пациентов. Изолированное поражение слюнных желез выявлено у 24, сочетание с поражением слезных желез – у 6 пациентов. Сухой синдром диагностирован у 8 пациентов. У всех пациентов были системные проявления: конституциональные нарушения – 50%, суставной синдром – 83,3%, лимфаденопатия – 73,3%, кожный синдром – 60%, поражение легких – 23,3%. Из гематологических нарушений чаще фиксировались лейко/лимфопения – у 30%, поликлональная гипергаммаглобулинемия – у 26,7% пациентов. У всех больных выявлялся положительный антинуклеарный фактор (АНФ), 60% пациентов были позитивными по Ro-антителам, 56,7% – имели положительный ревматоидный фактор (РФ). Наиболее распространенным сочетанием иммунологических нарушений было наличие АНФ, РФ и анти-Ro-антител (40% пациентов). Объем проводимой терапии обосновывался ведущими проявлениями и активностью РЗ: нестероидные противовоспалительные препараты получали 66,7%, глюкокортикоиды – 80%, базисную противовоспалительную терапию метотрексатом – 46,7%, азатиоприном – 20%, гидроксихлорохином – 43,3%, микофенолата мофетилом – 10%, циклофосфаном – 3,4% пациентов. Опыт применения генно-инженерных биологических препаратов имели 66,7% пациентов.
Заключение. Раннее выявление СШ при РЗ у детей накладывает существенный отпечаток на выбор терапевтической тактики и прогноз. У детей СШ длительно не имеет клинических проявлений. Такие симптомы, как гипергаммаглобулинемия, положительный РФ без стойкого артрита, неспецифические поражения кожи, рецидивирующий паротит, должны настораживать врачей в плане развития СШ.
Ключевые слова: детский возраст, синдром Шегрена у детей, рецидивирующий неинфекционный паротит.
Materials and methods. The study included all consequently patients, who hospitalized to the pediatric department of V.A. Nasonova Scientific and Research Institute of Rheumatology from January 2013 to December 2018, which verified the diagnosis of the SS.
Results. The diagnosis of SS was established in 30 patients, among whom there were only 5 (16.7%) boys, the ratio of boys and girls was 1:5. According to the results of the examination, the following diagnoses were verified: 4 – primary SS, 9 – systemic lupus erythematosus with SS, 10 – juvenile rheumatoid arthritis with SS, 3 – mixed connective tissue disease, 3 – overlap syndrome, 1 – systemic sclerosis with SS. The median age of rheumatic disease onset was 10.4 (7.0; 13.75) years. The median of disease duration at the time of SS verification – 3.0 (0.85; 4.4) years. Recurrent parotitis were observed in 8 patients. 24 pts had isolated involvement of salivary glands, 6 – combined with lacrimal glands. Sicca syndrome was occurred in 8 patients. All patients had systemic manifestations: constitutional abnormalities – 50%, polyarthritis – 83.3%, lymphadenopathy – 73.3%, cutaneous involvement – 60%, pulmonary involvement – 23.3%. Of the hematological disorders, leuko/lymphopenia was more often recorded – in 30%, polyclonal hypergammaglobulinemia – in 26.7% of patients. ANA were detected in all cases, anti-Ro antibodies – 60%, a positive rheumatoid factor – 56.7% of patients. The most common combination of immunological disorders was the presence of ANA, RF and anti-Ro antibodies (40% of patients). The treatment for each patient was justified by the main manifestations and activity of rheumatic disease: 66.7% received nonsteroidal anti-inflammatory drugs, 80% – glucocorticoids, 46.7% – methotrexate, 20% – azathioprine, 43.3% – hydroxychloroquine, 10% – mycophenolatis mofetilum, 3.4% – cyclophosphamide. 66.7% of patients received the treatment of Biologics.
Conclusions. Early diagnosis of SS in children with rheumatic diseases significantly affects to the choice of treatment and prognosis.
In children the SS has no clinical manifestations for a long time. Such symptoms as a hypergammaglobulinemia, positive RF without persistant arthritis, nonspecific skin lesions, recurrent parotid swelling may help to diagnosis of SS.
Keywords: childhood, Sjögren's syndrome in children, recurrent non-infectious parotitis.
Материалы и методы. В исследование включены пациенты, последовательно госпитализированные в детское отделение НИИР им. В.А. Насоновой в период с января 2013 по декабрь 2018 г., которым по итогам обследования верифицирован диагноз СШ.
Результаты. Диагноз СШ установлен у 30 пациентов, среди которых было только 5 (16,7%) мальчиков, соотношение мальчиков и девочек 1:5. По итогам обследования верифицированы следующие диагнозы: у 4 – первичный СШ, у 9 – системная красная волчанка (СКВ) с СШ, у 10 – ювенильный ревматический артрит с СШ, у 3 – смешанное заболевание соединительной ткани, у 3 – перекрестный синдром, у 1 – системная склеродермия. Медиана возраста дебюта ревматического заболевания (РЗ) составила 10,4 (7,0; 13,75) года. Медиана длительности болезни на момент верификации СШ – 3,0 (0,85; 4,4) года. Рецидивирующие паротиты наблюдались у 8 пациентов. Изолированное поражение слюнных желез выявлено у 24, сочетание с поражением слезных желез – у 6 пациентов. Сухой синдром диагностирован у 8 пациентов. У всех пациентов были системные проявления: конституциональные нарушения – 50%, суставной синдром – 83,3%, лимфаденопатия – 73,3%, кожный синдром – 60%, поражение легких – 23,3%. Из гематологических нарушений чаще фиксировались лейко/лимфопения – у 30%, поликлональная гипергаммаглобулинемия – у 26,7% пациентов. У всех больных выявлялся положительный антинуклеарный фактор (АНФ), 60% пациентов были позитивными по Ro-антителам, 56,7% – имели положительный ревматоидный фактор (РФ). Наиболее распространенным сочетанием иммунологических нарушений было наличие АНФ, РФ и анти-Ro-антител (40% пациентов). Объем проводимой терапии обосновывался ведущими проявлениями и активностью РЗ: нестероидные противовоспалительные препараты получали 66,7%, глюкокортикоиды – 80%, базисную противовоспалительную терапию метотрексатом – 46,7%, азатиоприном – 20%, гидроксихлорохином – 43,3%, микофенолата мофетилом – 10%, циклофосфаном – 3,4% пациентов. Опыт применения генно-инженерных биологических препаратов имели 66,7% пациентов.
Заключение. Раннее выявление СШ при РЗ у детей накладывает существенный отпечаток на выбор терапевтической тактики и прогноз. У детей СШ длительно не имеет клинических проявлений. Такие симптомы, как гипергаммаглобулинемия, положительный РФ без стойкого артрита, неспецифические поражения кожи, рецидивирующий паротит, должны настораживать врачей в плане развития СШ.
Ключевые слова: детский возраст, синдром Шегрена у детей, рецидивирующий неинфекционный паротит.
________________________________________________
Materials and methods. The study included all consequently patients, who hospitalized to the pediatric department of V.A. Nasonova Scientific and Research Institute of Rheumatology from January 2013 to December 2018, which verified the diagnosis of the SS.
Results. The diagnosis of SS was established in 30 patients, among whom there were only 5 (16.7%) boys, the ratio of boys and girls was 1:5. According to the results of the examination, the following diagnoses were verified: 4 – primary SS, 9 – systemic lupus erythematosus with SS, 10 – juvenile rheumatoid arthritis with SS, 3 – mixed connective tissue disease, 3 – overlap syndrome, 1 – systemic sclerosis with SS. The median age of rheumatic disease onset was 10.4 (7.0; 13.75) years. The median of disease duration at the time of SS verification – 3.0 (0.85; 4.4) years. Recurrent parotitis were observed in 8 patients. 24 pts had isolated involvement of salivary glands, 6 – combined with lacrimal glands. Sicca syndrome was occurred in 8 patients. All patients had systemic manifestations: constitutional abnormalities – 50%, polyarthritis – 83.3%, lymphadenopathy – 73.3%, cutaneous involvement – 60%, pulmonary involvement – 23.3%. Of the hematological disorders, leuko/lymphopenia was more often recorded – in 30%, polyclonal hypergammaglobulinemia – in 26.7% of patients. ANA were detected in all cases, anti-Ro antibodies – 60%, a positive rheumatoid factor – 56.7% of patients. The most common combination of immunological disorders was the presence of ANA, RF and anti-Ro antibodies (40% of patients). The treatment for each patient was justified by the main manifestations and activity of rheumatic disease: 66.7% received nonsteroidal anti-inflammatory drugs, 80% – glucocorticoids, 46.7% – methotrexate, 20% – azathioprine, 43.3% – hydroxychloroquine, 10% – mycophenolatis mofetilum, 3.4% – cyclophosphamide. 66.7% of patients received the treatment of Biologics.
Conclusions. Early diagnosis of SS in children with rheumatic diseases significantly affects to the choice of treatment and prognosis.
In children the SS has no clinical manifestations for a long time. Such symptoms as a hypergammaglobulinemia, positive RF without persistant arthritis, nonspecific skin lesions, recurrent parotid swelling may help to diagnosis of SS.
Keywords: childhood, Sjögren's syndrome in children, recurrent non-infectious parotitis.
Список литературы
1. Васильев В.И. Клиника, диагностика и дифференциальная диагностика болезни Шегрена. Русский медицинский журнал. 2008;16(10):638-48 [Vasiliev VI. Clinic, diagnosis and differential diagnosis of Sjogren's disease. Rossiiskii medicinskii journal. 2008;16(10):638-48 (In Russ.)].
2. Virdee S, Greenan-Barrett J, Ciurtin C. A systematic review of primary Sjögren’s syndrome in male and paediatric populations. Clin Rheumatol. 2017;36:2225-36. doi: 10.1007/s10067-017-3745-z
3. Cimaz R, Casadei A, Rose C, Bartunkova J, Sediva A, Falcini F, et al. Primary Sjogren syndrome in the paediatric age: a multicentre survey. Eur J Pediatr. 2003;162(10):661-5. doi: 10.1007/s00431-003-1277-9
4. Movva S, Carsons S. Review of pediatric Sjogren’s syndrome. Pediatr Allergy Immunol Pulmonol. 2014;27(3):111-46. doi: 10.1089/ped.2013.03 26
5. Stiller M, Golder W, Doring E, Biedermann T. Primary and secondary Sjogren’s syndrome in children – a comparative study. Clin Oral Investig. 2000;4(3):176-82. doi: 10.1007/s007840000070
6. Tomiita M, Saito K, Kohno Y, Shimojo N, Fujikawa S, Niimi H. The clinical features of Sjögren's syndrome in Japanese children. Acta Paediatr Jpn. 1997 Apr;39(2):268-72. PubMed PMID: 9141270
7. de Souza TR, Silva IH, Carvalho AT, Gomes VB, Duarte AP, Leão JC, Gueiros LA. Juvenile Sjögren syndrome: distinctive age, unique findings. Pediatr Dent. 2012 Sep-Oct;34(5):427-30. Review. PubMed PMID:2321 1922
8. Hara T, Nagata M, Mizuno Y, Ura Y, Matsuo M, Ueda K. Recurrent parotid swelling in children: clinical features useful for differential diagnosis of Sjögren's syndrome. Acta Paediatr. 1992 Jun-Jul;81(6-7):547-9. PubMed PMID:1392371
9. Brito-Zerón P, Kostov B, Solans R, Fraile G, Suárez-Cuervo C, Casanovas A,Rascón FJ, Qanneta R, Pérez-Alvarez R, Ripoll M, Akasbi M, Pinilla B, Bosch JA,Nava-Mateos J, Díaz-López B, Morera-Morales ML, Gheitasi H, Retamozo S,Ramos-Casals M; SS Study Group, Autoimmune Diseases Study Group (GEAS), Spanish Society of Internal Medicine (SEMI). Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index(ESSDAI) in 1045 patients. Ann Rheum Dis. 2016 Feb;75(2):348-55. doi:10.1136/annrheumdis-2014-206418. Epub 2014 Nov 28. PubMed PMID: 25433020
10. Singer NG, Tomanova-Soltys I, Lowe R. Sjögren's syndrome in childhood. Curr Rheumatol Rep. 2008 Apr;10(2):147-55. Review. PubMed PMID: 18460271
11. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76:9-16. doi: 10.1136/annrheumdis-2016-210571
12. Yokogawa N, Lieberman SM, Sherry DD, Vivino FB. Features of childhood Sjögren's syndrome in comparison to adult Sjögren's syndrome: considerations in establishing child-specific diagnostic criteria. Clin Exp Rheumatol. 2016 Mar-Apr;34(2):343-51. Epub 2016 Jan 20. PubMed PMID: 26812559
13. Mossel E, Delli K, van Nimwegen JF, Stel AJ, Kroese FGM, Spijkervet FKL, Vissink A, Arends S, Bootsma H. EULAR US-pSS Study Group. Ultrasonography of major salivary glands compared with parotid and labial gland biopsy and classification criteria in patients with clinically suspected primary Sjögren's syndrome. Ann Rheum Dis. 2017 Nov;76(11):1883-9. doi: 10.1136/annrheumdis-2017-211250 Epub 2017 Jul 28. PubMed PMID: 28754802
14. Bolstad AI, Jonsson R. Genetic aspects of Sjögren's syndrome. Arthritis Research & Therapy. 2002;4:353-9. doi: 10.1186/ar599
15. Fayyaz A, Kurien BT, Scofield RH. Autoantibodies in Sjögren's Syndrome. Rheum Dis Clin North Am. 2016;42(3):419-34. doi: 10.1016/j. rdc.2016.03.002
16. Theander E, Jonsson R, Sjöström B, Brokstad K, Olsson P, Henriksson G. Prediction of Sjögren's Syndrome Years Before Diagnosis and Identification of Patients With Early Onset and Severe Disease Course by Autoantibody Profiling. Arthritis Rheumatol. 2015 Sep;67(9):2427-36. doi: 10.1002/art.39214. PubMed PMID:26109563
17. Ramos-Casals M, Brito-Zerón P, Font J. The overlap of Sjögren’s syndrome with other systemic autoimmune diseases. Semin Arthritis Rheum. 2007;36:246-55. doi: 10.1016/j.semarthrit.2006.08.007
18. Hernández-Molina G, Zamora-Legoff T, Romero-Díaz J, Nuñez-Alvarez CA, Cárdenas-Velázquez F, Hernández-Hernández C, Calderillo ML, Marroquín M, Recillas-Gispert C, Ávila-Casado C, Sánchez-Guerrero J. Predicting Sjögren’s syndrome in patients with recent-onset SLE. Rheumatology. 2013 Aug. 1;52(Issue 8):1438-42. doi: 10.1093/rheu matology/ket141
19. Manoussakis M, Georgopoulou C, Zintzaras E, et al. Sjögren’s syndrome associated with systemic lupus erythematosus. Arthritis Rheum. 2004;50:882-91. doi: 10.1002/art.20093
20. Baer A, Maynard J, Shaikh F, et al. Secondary Sjögren’s syndrome in systemic lupus erythematosus defines a distinct disease subset. J Rheumatol. 2010;3:1143-9. doi: 10.3899/jrheum.090804. Epub 2010 Apr 1
21. Valim V, Trevisani VF, Pasoto SG, et al. Recommendations for the treatment of Sjögren's syndrome. Rev Bras Reumatol. 2015;55:446-57. doi: 10.1016/j.rbre.2015.08.002
22. Carsons SE, Vivino FB, Parke A, Carteron N, Sankar V, Brasington R, Brennan MT, Ehlers W, Fox R, Scofield H, Hammitt KM, Birnbaum J, Kassan S, Mandel S. Treatment Guidelines for Rheumatologic Manifestations of Sjögren's Syndrome: Use of Biologic Agents, Management of Fatigue, and Inflammatory Musculoskeletal Pain. Arthritis Care Res (Hoboken). 2017 Apr;69(4):517-27. doi: 10.1002/acr.22968 Epub 2017 Mar 3. Review. PubMed PMID: 27390247
2. Virdee S, Greenan-Barrett J, Ciurtin C. A systematic review of primary Sjögren’s syndrome in male and paediatric populations. Clin Rheumatol. 2017;36:2225-36. doi: 10.1007/s10067-017-3745-z
3. Cimaz R, Casadei A, Rose C, Bartunkova J, Sediva A, Falcini F, et al. Primary Sjogren syndrome in the paediatric age: a multicentre survey. Eur J Pediatr. 2003;162(10):661-5. doi: 10.1007/s00431-003-1277-9
4. Movva S, Carsons S. Review of pediatric Sjogren’s syndrome. Pediatr Allergy Immunol Pulmonol. 2014;27(3):111-46. doi: 10.1089/ped.2013.03 26
5. Stiller M, Golder W, Doring E, Biedermann T. Primary and secondary Sjogren’s syndrome in children – a comparative study. Clin Oral Investig. 2000;4(3):176-82. doi: 10.1007/s007840000070
6. Tomiita M, Saito K, Kohno Y, Shimojo N, Fujikawa S, Niimi H. The clinical features of Sjögren's syndrome in Japanese children. Acta Paediatr Jpn. 1997 Apr;39(2):268-72. PubMed PMID: 9141270
7. de Souza TR, Silva IH, Carvalho AT, Gomes VB, Duarte AP, Leão JC, Gueiros LA. Juvenile Sjögren syndrome: distinctive age, unique findings. Pediatr Dent. 2012 Sep-Oct;34(5):427-30. Review. PubMed PMID:2321 1922
8. Hara T, Nagata M, Mizuno Y, Ura Y, Matsuo M, Ueda K. Recurrent parotid swelling in children: clinical features useful for differential diagnosis of Sjögren's syndrome. Acta Paediatr. 1992 Jun-Jul;81(6-7):547-9. PubMed PMID:1392371
9. Brito-Zerón P, Kostov B, Solans R, Fraile G, Suárez-Cuervo C, Casanovas A,Rascón FJ, Qanneta R, Pérez-Alvarez R, Ripoll M, Akasbi M, Pinilla B, Bosch JA,Nava-Mateos J, Díaz-López B, Morera-Morales ML, Gheitasi H, Retamozo S,Ramos-Casals M; SS Study Group, Autoimmune Diseases Study Group (GEAS), Spanish Society of Internal Medicine (SEMI). Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index(ESSDAI) in 1045 patients. Ann Rheum Dis. 2016 Feb;75(2):348-55. doi:10.1136/annrheumdis-2014-206418. Epub 2014 Nov 28. PubMed PMID: 25433020
10. Singer NG, Tomanova-Soltys I, Lowe R. Sjögren's syndrome in childhood. Curr Rheumatol Rep. 2008 Apr;10(2):147-55. Review. PubMed PMID: 18460271
11. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76:9-16. doi: 10.1136/annrheumdis-2016-210571
12. Yokogawa N, Lieberman SM, Sherry DD, Vivino FB. Features of childhood Sjögren's syndrome in comparison to adult Sjögren's syndrome: considerations in establishing child-specific diagnostic criteria. Clin Exp Rheumatol. 2016 Mar-Apr;34(2):343-51. Epub 2016 Jan 20. PubMed PMID: 26812559
13. Mossel E, Delli K, van Nimwegen JF, Stel AJ, Kroese FGM, Spijkervet FKL, Vissink A, Arends S, Bootsma H. EULAR US-pSS Study Group. Ultrasonography of major salivary glands compared with parotid and labial gland biopsy and classification criteria in patients with clinically suspected primary Sjögren's syndrome. Ann Rheum Dis. 2017 Nov;76(11):1883-9. doi: 10.1136/annrheumdis-2017-211250 Epub 2017 Jul 28. PubMed PMID: 28754802
14. Bolstad AI, Jonsson R. Genetic aspects of Sjögren's syndrome. Arthritis Research & Therapy. 2002;4:353-9. doi: 10.1186/ar599
15. Fayyaz A, Kurien BT, Scofield RH. Autoantibodies in Sjögren's Syndrome. Rheum Dis Clin North Am. 2016;42(3):419-34. doi: 10.1016/j. rdc.2016.03.002
16. Theander E, Jonsson R, Sjöström B, Brokstad K, Olsson P, Henriksson G. Prediction of Sjögren's Syndrome Years Before Diagnosis and Identification of Patients With Early Onset and Severe Disease Course by Autoantibody Profiling. Arthritis Rheumatol. 2015 Sep;67(9):2427-36. doi: 10.1002/art.39214. PubMed PMID:26109563
17. Ramos-Casals M, Brito-Zerón P, Font J. The overlap of Sjögren’s syndrome with other systemic autoimmune diseases. Semin Arthritis Rheum. 2007;36:246-55. doi: 10.1016/j.semarthrit.2006.08.007
18. Hernández-Molina G, Zamora-Legoff T, Romero-Díaz J, Nuñez-Alvarez CA, Cárdenas-Velázquez F, Hernández-Hernández C, Calderillo ML, Marroquín M, Recillas-Gispert C, Ávila-Casado C, Sánchez-Guerrero J. Predicting Sjögren’s syndrome in patients with recent-onset SLE. Rheumatology. 2013 Aug. 1;52(Issue 8):1438-42. doi: 10.1093/rheu matology/ket141
19. Manoussakis M, Georgopoulou C, Zintzaras E, et al. Sjögren’s syndrome associated with systemic lupus erythematosus. Arthritis Rheum. 2004;50:882-91. doi: 10.1002/art.20093
20. Baer A, Maynard J, Shaikh F, et al. Secondary Sjögren’s syndrome in systemic lupus erythematosus defines a distinct disease subset. J Rheumatol. 2010;3:1143-9. doi: 10.3899/jrheum.090804. Epub 2010 Apr 1
21. Valim V, Trevisani VF, Pasoto SG, et al. Recommendations for the treatment of Sjögren's syndrome. Rev Bras Reumatol. 2015;55:446-57. doi: 10.1016/j.rbre.2015.08.002
22. Carsons SE, Vivino FB, Parke A, Carteron N, Sankar V, Brasington R, Brennan MT, Ehlers W, Fox R, Scofield H, Hammitt KM, Birnbaum J, Kassan S, Mandel S. Treatment Guidelines for Rheumatologic Manifestations of Sjögren's Syndrome: Use of Biologic Agents, Management of Fatigue, and Inflammatory Musculoskeletal Pain. Arthritis Care Res (Hoboken). 2017 Apr;69(4):517-27. doi: 10.1002/acr.22968 Epub 2017 Mar 3. Review. PubMed PMID: 27390247
2. Virdee S, Greenan-Barrett J, Ciurtin C. A systematic review of primary Sjögren’s syndrome in male and paediatric populations. Clin Rheumatol. 2017;36:2225-36. doi: 10.1007/s10067-017-3745-z
3. Cimaz R, Casadei A, Rose C, Bartunkova J, Sediva A, Falcini F, et al. Primary Sjogren syndrome in the paediatric age: a multicentre survey. Eur J Pediatr. 2003;162(10):661-5. doi: 10.1007/s00431-003-1277-9
4. Movva S, Carsons S. Review of pediatric Sjogren’s syndrome. Pediatr Allergy Immunol Pulmonol. 2014;27(3):111-46. doi: 10.1089/ped.2013.03 26
5. Stiller M, Golder W, Doring E, Biedermann T. Primary and secondary Sjogren’s syndrome in children – a comparative study. Clin Oral Investig. 2000;4(3):176-82. doi: 10.1007/s007840000070
6. Tomiita M, Saito K, Kohno Y, Shimojo N, Fujikawa S, Niimi H. The clinical features of Sjögren's syndrome in Japanese children. Acta Paediatr Jpn. 1997 Apr;39(2):268-72. PubMed PMID: 9141270
7. de Souza TR, Silva IH, Carvalho AT, Gomes VB, Duarte AP, Leão JC, Gueiros LA. Juvenile Sjögren syndrome: distinctive age, unique findings. Pediatr Dent. 2012 Sep-Oct;34(5):427-30. Review. PubMed PMID:2321 1922
8. Hara T, Nagata M, Mizuno Y, Ura Y, Matsuo M, Ueda K. Recurrent parotid swelling in children: clinical features useful for differential diagnosis of Sjögren's syndrome. Acta Paediatr. 1992 Jun-Jul;81(6-7):547-9. PubMed PMID:1392371
9. Brito-Zerón P, Kostov B, Solans R, Fraile G, Suárez-Cuervo C, Casanovas A,Rascón FJ, Qanneta R, Pérez-Alvarez R, Ripoll M, Akasbi M, Pinilla B, Bosch JA,Nava-Mateos J, Díaz-López B, Morera-Morales ML, Gheitasi H, Retamozo S,Ramos-Casals M; SS Study Group, Autoimmune Diseases Study Group (GEAS), Spanish Society of Internal Medicine (SEMI). Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index(ESSDAI) in 1045 patients. Ann Rheum Dis. 2016 Feb;75(2):348-55. doi:10.1136/annrheumdis-2014-206418. Epub 2014 Nov 28. PubMed PMID: 25433020
10. Singer NG, Tomanova-Soltys I, Lowe R. Sjögren's syndrome in childhood. Curr Rheumatol Rep. 2008 Apr;10(2):147-55. Review. PubMed PMID: 18460271
11. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76:9-16. doi: 10.1136/annrheumdis-2016-210571
12. Yokogawa N, Lieberman SM, Sherry DD, Vivino FB. Features of childhood Sjögren's syndrome in comparison to adult Sjögren's syndrome: considerations in establishing child-specific diagnostic criteria. Clin Exp Rheumatol. 2016 Mar-Apr;34(2):343-51. Epub 2016 Jan 20. PubMed PMID: 26812559
13. Mossel E, Delli K, van Nimwegen JF, Stel AJ, Kroese FGM, Spijkervet FKL, Vissink A, Arends S, Bootsma H. EULAR US-pSS Study Group. Ultrasonography of major salivary glands compared with parotid and labial gland biopsy and classification criteria in patients with clinically suspected primary Sjögren's syndrome. Ann Rheum Dis. 2017 Nov;76(11):1883-9. doi: 10.1136/annrheumdis-2017-211250 Epub 2017 Jul 28. PubMed PMID: 28754802
14. Bolstad AI, Jonsson R. Genetic aspects of Sjögren's syndrome. Arthritis Research & Therapy. 2002;4:353-9. doi: 10.1186/ar599
15. Fayyaz A, Kurien BT, Scofield RH. Autoantibodies in Sjögren's Syndrome. Rheum Dis Clin North Am. 2016;42(3):419-34. doi: 10.1016/j. rdc.2016.03.002
16. Theander E, Jonsson R, Sjöström B, Brokstad K, Olsson P, Henriksson G. Prediction of Sjögren's Syndrome Years Before Diagnosis and Identification of Patients With Early Onset and Severe Disease Course by Autoantibody Profiling. Arthritis Rheumatol. 2015 Sep;67(9):2427-36. doi: 10.1002/art.39214. PubMed PMID:26109563
17. Ramos-Casals M, Brito-Zerón P, Font J. The overlap of Sjögren’s syndrome with other systemic autoimmune diseases. Semin Arthritis Rheum. 2007;36:246-55. doi: 10.1016/j.semarthrit.2006.08.007
18. Hernández-Molina G, Zamora-Legoff T, Romero-Díaz J, Nuñez-Alvarez CA, Cárdenas-Velázquez F, Hernández-Hernández C, Calderillo ML, Marroquín M, Recillas-Gispert C, Ávila-Casado C, Sánchez-Guerrero J. Predicting Sjögren’s syndrome in patients with recent-onset SLE. Rheumatology. 2013 Aug. 1;52(Issue 8):1438-42. doi: 10.1093/rheu matology/ket141
19. Manoussakis M, Georgopoulou C, Zintzaras E, et al. Sjögren’s syndrome associated with systemic lupus erythematosus. Arthritis Rheum. 2004;50:882-91. doi: 10.1002/art.20093
20. Baer A, Maynard J, Shaikh F, et al. Secondary Sjögren’s syndrome in systemic lupus erythematosus defines a distinct disease subset. J Rheumatol. 2010;3:1143-9. doi: 10.3899/jrheum.090804. Epub 2010 Apr 1
21. Valim V, Trevisani VF, Pasoto SG, et al. Recommendations for the treatment of Sjögren's syndrome. Rev Bras Reumatol. 2015;55:446-57. doi: 10.1016/j.rbre.2015.08.002
22. Carsons SE, Vivino FB, Parke A, Carteron N, Sankar V, Brasington R, Brennan MT, Ehlers W, Fox R, Scofield H, Hammitt KM, Birnbaum J, Kassan S, Mandel S. Treatment Guidelines for Rheumatologic Manifestations of Sjögren's Syndrome: Use of Biologic Agents, Management of Fatigue, and Inflammatory Musculoskeletal Pain. Arthritis Care Res (Hoboken). 2017 Apr;69(4):517-27. doi: 10.1002/acr.22968 Epub 2017 Mar 3. Review. PubMed PMID: 27390247
________________________________________________
2. Virdee S, Greenan-Barrett J, Ciurtin C. A systematic review of primary Sjögren’s syndrome in male and paediatric populations. Clin Rheumatol. 2017;36:2225-36. doi: 10.1007/s10067-017-3745-z
3. Cimaz R, Casadei A, Rose C, Bartunkova J, Sediva A, Falcini F, et al. Primary Sjogren syndrome in the paediatric age: a multicentre survey. Eur J Pediatr. 2003;162(10):661-5. doi: 10.1007/s00431-003-1277-9
4. Movva S, Carsons S. Review of pediatric Sjogren’s syndrome. Pediatr Allergy Immunol Pulmonol. 2014;27(3):111-46. doi: 10.1089/ped.2013.03 26
5. Stiller M, Golder W, Doring E, Biedermann T. Primary and secondary Sjogren’s syndrome in children – a comparative study. Clin Oral Investig. 2000;4(3):176-82. doi: 10.1007/s007840000070
6. Tomiita M, Saito K, Kohno Y, Shimojo N, Fujikawa S, Niimi H. The clinical features of Sjögren's syndrome in Japanese children. Acta Paediatr Jpn. 1997 Apr;39(2):268-72. PubMed PMID: 9141270
7. de Souza TR, Silva IH, Carvalho AT, Gomes VB, Duarte AP, Leão JC, Gueiros LA. Juvenile Sjögren syndrome: distinctive age, unique findings. Pediatr Dent. 2012 Sep-Oct;34(5):427-30. Review. PubMed PMID:2321 1922
8. Hara T, Nagata M, Mizuno Y, Ura Y, Matsuo M, Ueda K. Recurrent parotid swelling in children: clinical features useful for differential diagnosis of Sjögren's syndrome. Acta Paediatr. 1992 Jun-Jul;81(6-7):547-9. PubMed PMID:1392371
9. Brito-Zerón P, Kostov B, Solans R, Fraile G, Suárez-Cuervo C, Casanovas A,Rascón FJ, Qanneta R, Pérez-Alvarez R, Ripoll M, Akasbi M, Pinilla B, Bosch JA,Nava-Mateos J, Díaz-López B, Morera-Morales ML, Gheitasi H, Retamozo S,Ramos-Casals M; SS Study Group, Autoimmune Diseases Study Group (GEAS), Spanish Society of Internal Medicine (SEMI). Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index(ESSDAI) in 1045 patients. Ann Rheum Dis. 2016 Feb;75(2):348-55. doi:10.1136/annrheumdis-2014-206418. Epub 2014 Nov 28. PubMed PMID: 25433020
10. Singer NG, Tomanova-Soltys I, Lowe R. Sjögren's syndrome in childhood. Curr Rheumatol Rep. 2008 Apr;10(2):147-55. Review. PubMed PMID: 18460271
11. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76:9-16. doi: 10.1136/annrheumdis-2016-210571
12. Yokogawa N, Lieberman SM, Sherry DD, Vivino FB. Features of childhood Sjögren's syndrome in comparison to adult Sjögren's syndrome: considerations in establishing child-specific diagnostic criteria. Clin Exp Rheumatol. 2016 Mar-Apr;34(2):343-51. Epub 2016 Jan 20. PubMed PMID: 26812559
13. Mossel E, Delli K, van Nimwegen JF, Stel AJ, Kroese FGM, Spijkervet FKL, Vissink A, Arends S, Bootsma H. EULAR US-pSS Study Group. Ultrasonography of major salivary glands compared with parotid and labial gland biopsy and classification criteria in patients with clinically suspected primary Sjögren's syndrome. Ann Rheum Dis. 2017 Nov;76(11):1883-9. doi: 10.1136/annrheumdis-2017-211250 Epub 2017 Jul 28. PubMed PMID: 28754802
14. Bolstad AI, Jonsson R. Genetic aspects of Sjögren's syndrome. Arthritis Research & Therapy. 2002;4:353-9. doi: 10.1186/ar599
15. Fayyaz A, Kurien BT, Scofield RH. Autoantibodies in Sjögren's Syndrome. Rheum Dis Clin North Am. 2016;42(3):419-34. doi: 10.1016/j. rdc.2016.03.002
16. Theander E, Jonsson R, Sjöström B, Brokstad K, Olsson P, Henriksson G. Prediction of Sjögren's Syndrome Years Before Diagnosis and Identification of Patients With Early Onset and Severe Disease Course by Autoantibody Profiling. Arthritis Rheumatol. 2015 Sep;67(9):2427-36. doi: 10.1002/art.39214. PubMed PMID:26109563
17. Ramos-Casals M, Brito-Zerón P, Font J. The overlap of Sjögren’s syndrome with other systemic autoimmune diseases. Semin Arthritis Rheum. 2007;36:246-55. doi: 10.1016/j.semarthrit.2006.08.007
18. Hernández-Molina G, Zamora-Legoff T, Romero-Díaz J, Nuñez-Alvarez CA, Cárdenas-Velázquez F, Hernández-Hernández C, Calderillo ML, Marroquín M, Recillas-Gispert C, Ávila-Casado C, Sánchez-Guerrero J. Predicting Sjögren’s syndrome in patients with recent-onset SLE. Rheumatology. 2013 Aug. 1;52(Issue 8):1438-42. doi: 10.1093/rheu matology/ket141
19. Manoussakis M, Georgopoulou C, Zintzaras E, et al. Sjögren’s syndrome associated with systemic lupus erythematosus. Arthritis Rheum. 2004;50:882-91. doi: 10.1002/art.20093
20. Baer A, Maynard J, Shaikh F, et al. Secondary Sjögren’s syndrome in systemic lupus erythematosus defines a distinct disease subset. J Rheumatol. 2010;3:1143-9. doi: 10.3899/jrheum.090804. Epub 2010 Apr 1
21. Valim V, Trevisani VF, Pasoto SG, et al. Recommendations for the treatment of Sjögren's syndrome. Rev Bras Reumatol. 2015;55:446-57. doi: 10.1016/j.rbre.2015.08.002
22. Carsons SE, Vivino FB, Parke A, Carteron N, Sankar V, Brasington R, Brennan MT, Ehlers W, Fox R, Scofield H, Hammitt KM, Birnbaum J, Kassan S, Mandel S. Treatment Guidelines for Rheumatologic Manifestations of Sjögren's Syndrome: Use of Biologic Agents, Management of Fatigue, and Inflammatory Musculoskeletal Pain. Arthritis Care Res (Hoboken). 2017 Apr;69(4):517-27. doi: 10.1002/acr.22968 Epub 2017 Mar 3. Review. PubMed PMID: 27390247
Авторы
М.И. Каледа, И.П. Никишина, А.Н. Латыпова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», лаборатория ревматических заболеваний детского возраста c реабилитационной группой, Москва, Россия
V.A. Nasonova Scientific and Research Institute of Rheumatology, Pediatric Department, Moscow, Russia
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», лаборатория ревматических заболеваний детского возраста c реабилитационной группой, Москва, Россия
________________________________________________
V.A. Nasonova Scientific and Research Institute of Rheumatology, Pediatric Department, Moscow, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.